Nuburu stock rises on strategic execution milestones planned for 2026

Investing.com – Indonesia stocks were higher after the close on Tuesday, as gains in the Infrastructure, Financials and Agriculture sectors led shares higher.

At the close in Jakarta, the IDX Composite Index gained 0.07%.

The best performers of the session on the IDX Composite Index were Chitose Internasional Tbk (JK:CINT), which rose 34.81% or 63.00 points to trade at 244.00 at the close. Meanwhile, Polychem Indonesia Tbk (JK:ADMG) added 25.97% or 47.00 points to end at 228.00 and PP Presisi Tbk PT (JK:PPRE) was up 24.64% or 34.00 points to 172.00 in late trade.

The worst performers of the session were Ulima Nitra PT (JK:UNIQ), which fell 14.83% or 62.00 points to trade at 356.00 at the close. Mustika Ratu Tbk (JK:MRAT) declined 14.78% or 85.00 points to end at 490.00 and Pudjiadi Prestige Tbk (JK:PUDP) was down 14.29% or 95.00 points to 570.00.

Rising stocks outnumbered declining ones on the Jakarta Stock Exchange by 349 to 331 and 170 ended unchanged.

Shares in Chitose Internasional Tbk (JK:CINT) rose to 3-years highs; rising 34.81% or 63.00 to 244.00. Shares in Polychem Indonesia Tbk (JK:ADMG) rose to 3-years highs; rising 25.97% or 47.00 to 228.00. Shares in PP Presisi Tbk PT (JK:PPRE) rose to 3-years highs; up 24.64% or 34.00 to 172.00.

Crude oil for February delivery was up 0.12% or 0.07 to $58.15 a barrel. Elsewhere in commodities trading, Brent oil for delivery in March rose 0.10% or 0.06 to hit $61.55 a barrel, while the February Gold Futures contract rose 0.69% or 30.10 to trade at $4,373.70 a troy ounce.

USD/IDR was up 0.03% to 16,768.60, while AUD/IDR rose 0.08% to 11,236.74.

The US Dollar Index Futures was down 0.05% at 97.69.

Investing.com – U.S. stocks were lower after the close on Monday, as losses in the Basic Materials, Consumer Goods and Technology sectors led shares lower.

At the close in NYSE, the Dow Jones Industrial Average declined 0.51%, while the S&P 500 index fell 0.35%, and the NASDAQ Composite index fell 0.50%.

The best performers of the session on the Dow Jones Industrial Average were Walmart Inc (NASDAQ:WMT), which rose 0.72% or 0.81 points to trade at 112.55 at the close. Meanwhile, Chevron Corp (NYSE:CVX) added 0.65% or 0.97 points to end at 150.99 and Walt Disney Company (NYSE:DIS) was up 0.55% or 0.63 points to 114.19 in late trade.

The worst performers of the session were Goldman Sachs Group Inc (NYSE:GS), which fell 1.61% or 14.62 points to trade at 892.42 at the close. American Express Company (NYSE:AXP) declined 1.50% or 5.72 points to end at 375.33 and JPMorgan Chase & Co (NYSE:JPM) was down 1.26% or 4.14 points to 323.77.

The top performers on the S&P 500 were Micron Technology Inc (NASDAQ:MU) which rose 3.42% to 294.41, eBay Inc (NASDAQ:EBAY) which was up 2.99% to settle at 87.76 and Verisk Analytics Inc (NASDAQ:VRSK) which gained 2.00% to close at 224.74.

The worst performers were Newmont Goldcorp Corp (NYSE:NEM) which was down 5.64% to 99.81 in late trade, Albemarle Corp (NYSE:ALB) which lost 3.62% to settle at 144.58 and Tesla Inc (NASDAQ:TSLA) which was down 3.27% to 459.64 at the close.

The top performers on the NASDAQ Composite were Republic Power Group Ltd (NASDAQ:RPGL) which rose 157.46% to 0.68, Brand Engagement Network Inc (NASDAQ:BNAI) which was up 108.75% to settle at 2.51 and Society Pass Inc (NASDAQ:SOPA) which gained 60.99% to close at 2.93.

The worst performers were Mereo BioPharma Group PLC ADR (NASDAQ:MREO) which was down 87.65% to 0.29 in late trade, Ultragenyx (NASDAQ:RARE) which lost 42.32% to settle at 19.72 and New Era Helium Inc (NASDAQ:NUAI) which was down 41.08% to 2.69 at the close.

Falling stocks outnumbered advancing ones on the New York Stock Exchange by 1724 to 1014 and 95 ended unchanged; on the Nasdaq Stock Exchange, 2403 fell and 962 advanced, while 176 ended unchanged.

Shares in Micron Technology Inc (NASDAQ:MU) rose to all time highs; gaining 3.42% or 9.74 to 294.41. Shares in Mereo BioPharma Group PLC ADR (NASDAQ:MREO) fell to all time lows; losing 87.65% or 2.03 to 0.29. Shares in Ultragenyx (NASDAQ:RARE) fell to all time lows; losing 42.32% or 14.47 to 19.72.

The CBOE Volatility Index, which measures the implied volatility of S&P 500 options, was up 4.34% to 14.19.

Gold Futures for February delivery was down 4.49% or 204.45 to $4,348.25 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in February rose 1.87% or 1.06 to hit $57.80 a barrel, while the March Brent oil contract rose 1.59% or 0.96 to trade at $61.20 a barrel.

EUR/USD was unchanged 0.01% to 1.18, while USD/JPY fell 0.34% to 156.04.

The US Dollar Index Futures was up 0.02% at 97.72.

Investing.com – Brazil stocks were lower after the close on Monday, as losses in the Basic Materials, Real Estate and Public Utilities sectors led shares lower.

At the close in Sao Paulo, the Bovespa fell 0.38%.

The best performers of the session on the Bovespa were Brava Energia SA (BVMF:BRAV3), which rose 4.01% or 0.64 points to trade at 16.62 at the close. Meanwhile, Magazine Luiza SA (BVMF:MGLU3) added 1.95% or 0.18 points to end at 9.43 and Cvc Brasil ON (BVMF:CVCB3) was up 1.93% or 0.04 points to 2.11 in late trade.

The worst performers of the session were Companhia Siderurgica Nacional (BVMF:CSNA3), which fell 2.51% or 0.23 points to trade at 8.93 at the close. Bradespar SA (BVMF:BRAP4) declined 2.34% or 0.48 points to end at 20.01 and Cogna Educacao SA (BVMF:COGN3) was down 2.49% or 0.08 points to 3.13.

Rising stocks outnumbered declining ones on the B3 Stock Exchange by 516 to 438 and 53 ended unchanged.

The CBOE Brazil Etf Volatility, which measures the implied volatility of Bovespa options, was down 1.91% to 26.13 a new 1-month low.

Gold Futures for February delivery was down 4.24% or 193.05 to $4,359.65 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in February rose 2.11% or 1.20 to hit $57.94 a barrel, while the March US coffee C contract rose 0.30% or 1.05 to trade at $351.30 .

USD/BRL was up 0.50% to 5.57, while EUR/BRL rose 0.47% to 6.56.

The US Dollar Index Futures was up 0.04% at 97.74.

Investing.com -- Mixed Martial Arts Group Ltd (NYSE:MMA) stock tumbled 10.7% Monday following the company’s announcement of a $3 million private placement of preferred stock.

The company, operating as MMA.INC, has entered into definitive securities purchase agreements with accredited investors to issue and sell 4,285,714 shares of Series A Preferred Stock at $0.70 per share. The private placement, led by American Ventures LLC with Donald Trump Jr. among the investors, is expected to close on December 30, 2025.

In connection with the offering, MMA also issued placement agent warrants to purchase 342,857 ordinary shares at an exercise price of $0.70 per share. Dominari Securities LLC acted as the exclusive placement agent for the transaction.

The company plans to use the proceeds to expand its platform and build on its Web3 ecosystem strategy, including activating its partnership with UFC GYM and capitalizing on the growth of its BJJLink gym software platform.

Additionally, MMA entered into an Equity Purchase Agreement with American Ventures, which agreed to purchase up to $20 million of ordinary shares from the company over time, subject to certain restrictions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Eightco Holdings Inc. (NASDAQ:ORBS) stock jumped 12.8% Monday after the company announced its Board of Directors has approved a share buyback program of up to $125 million.

The company, which holds over 10% of the current Worldcoin (WLD) supply in circulation, is positioning the buyback as a strategic investment based on its current valuation and growth outlook. The move comes as Eightco continues to focus on developing a universal framework for digital identity and authentication.

"Management and the Board believe that based on Eightco’s current valuation and its pipeline for additional partnerships, the public stock is becoming an increasingly attractive investment," said Dan Ives, Chairman of Eightco. "This buyback program is a strong vote of confidence in Eightco’s strategy, and we see this as an opportunity to create meaningful value for shareholders as we execute on our vision."

CEO Kevin O’Donnell echoed this sentiment, emphasizing the company’s commitment to disciplined capital allocation while executing its long-term strategy. The company’s null by ORBS platform is focused on developing AI-resistant enterprise authentication solutions.

Eightco is backed by several strategic and institutional investors including BitMine (NASDAQ:BMNR), MOZAYYX, World Foundation, Wedbush, Coinfund, Discovery Capital Management, FalconX, Kraken, Pantera, GSR, and Brevan Howard.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Theriva Biologics Inc (NYSE American:TOVX) stock surged 25.4% in Monday premarket trading after the company announced receiving positive scientific advice from the European Medicines Agency (EMA) regarding its proposed Phase 3 clinical trial design for VCN-01 in pancreatic cancer treatment.

The EMA’s Committee for Medicinal Products for Human Use (CHMP) provided overall agreement with Theriva’s proposed pivotal trial of VCN-01 in combination with standard chemotherapy for first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC). The regulatory body endorsed key elements including sample size, repeated dosing of VCN-01, and an adaptive design approach.

Importantly, the EMA recognized the improved survival outcomes observed in patients who received multiple doses of VCN-01 in earlier trials and agreed with Theriva’s proposed "macrocycle" dosing regimen that would allow for more than two doses in the Phase 3 trial.

"We are very encouraged by the scientific advice we received from the EMA regarding our proposed pivotal Phase 3 trial of VCN-01 plus gemcitabine/nab-paclitaxel SoC in metastatic PDAC patients," said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.

The company plans to schedule an End-of-Phase 2 meeting with the FDA in the first half of 2026 to finalize the protocol for a multinational Phase 3 trial. Theriva is also seeking regulatory advice on a potential Phase 2/3 trial for VCN-01 in retinoblastoma, a rare childhood cancer.

Theriva reported having $15.5 million in cash and equivalents as of November 10, 2025, providing runway into the first quarter of 2027 as it completes regulatory interactions and pursues partnerships to support manufacturing scale-up and conduct of proposed pivotal trials.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.